Sich C, Improta S, Cowley D J, Guenet C, Merly J P, Teufel M, Saudek V
Department of Structural Biology and Cheminformatics, Department of Biotechnology, Sanofi-Synthelabo, Strasbourg, France.
Eur J Biochem. 2000 Sep;267(17):5342-55. doi: 10.1046/j.1432-1327.2000.01551.x.
The structure of a recently reported neurotrophic ligand, 3-(3-pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1, 2-dioxopentyl)-2-pyrrolidinecarboxylate, in complex with FKBP12 was determined using heteronuclear NMR spectroscopy. The inhibitor exhibits a binding mode analogous to that observed for the macrocycle FK506, used widely as an immunosuppressant, with the prolyl ring replacing the pipecolyl moiety and the amide bond in a trans conformation. However, fewer favourable protein-ligand interactions are detected in the structure of the complex, suggesting weaker binding compared with the immunosuppressant drug. Indeed, a micromolar dissociation constant was estimated from the NMR ligand titration profile, in contrast to the previously published nanomolar inhibition activity. Although the inhibitor possesses a remarkable structural simplicity with respect to FK506, 15N relaxation studies show that it induces similar effects on the protein dynamics, stabilizing the conformation of solvent-exposed residues which are important for mediating the interaction of immunophilin/ligand complexes with molecular targets and potentially for the transmission of the neurotrophic action of FKBP12 inhibitors.
利用异核核磁共振光谱法确定了一种最近报道的神经营养配体——3-(3-吡啶基)-1-丙基(2S)-1-(3,3-二甲基-1,2-二氧戊基)-2-吡咯烷羧酸酯与FKBP12形成的复合物的结构。该抑制剂呈现出与广泛用作免疫抑制剂的大环化合物FK506类似的结合模式,脯氨酰环取代了哌啶基部分,且酰胺键呈反式构象。然而,在复合物结构中检测到的有利的蛋白质-配体相互作用较少,这表明与免疫抑制药物相比,其结合较弱。实际上,根据核磁共振配体滴定曲线估算出微摩尔级的解离常数,这与之前报道的纳摩尔级抑制活性形成对比。尽管该抑制剂相对于FK506具有显著的结构简单性,但15N弛豫研究表明,它对蛋白质动力学产生类似的影响,稳定了溶剂暴露残基的构象,这些残基对于介导亲免素/配体复合物与分子靶点的相互作用以及FKBP12抑制剂神经营养作用的传递可能很重要。